Lifecore Biomedical, Inc.

NASDAQ:LFCR

Drug Manufacturers - Specialty & Generic

Healthcare
$6.40 +0.27%

+$0.02 today

Market cap
$242.60M
Beta
1.07
P/E (TTM)
-6.1
EPS (TTM)
-$0.91
52W Low $3.63High $8.98

Volume 0.15M

Average 0.29M

LFCR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Lifecore Biomedical, Inc.NASDAQ: LFCR

Research & Development · Q3 FY2026 · quarter ended Mar 2026

Research & development of $1.22M in Q3 FY2026

Q3 FY2026 research & development was $1.22M. Trailing-twelve-month research & development was $7.58M. Over 3 fiscal years it compounded at +1.8% a year.

Context

  • Research & development amounted to 6.4% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly research & development holds near $1.22M or moves back toward the trailing-twelve-month quarterly average of $1.9M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.22M-47.0% QoQ
Last fiscal yearMay 2025
$8.26M-3.7% YoY
LTMMar 2026
$7.58M— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-3.7%——
3-year CAGR+1.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
8.26M USD
Year-over-year change
-3.7%
4-year CAGR
+5.4%

Research & Development vs competitors

How LFCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Research & development amounts to 5.6% of revenue for LFCR, versus a peer median of 17.9%.
LFCR Competitors
Research & Development for LFCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIOABioAge Labs, Inc.LTM Mar 2026$83.27M USD+36.9%+34.3%807.2%
IMMPImmutep LimitedFY2025A$61.41M AUD+47.8%+25.1%1217.6%
PRQRProQR Therapeutics N.V.LTM Mar 2026€44.34M EUR+12.6%-7.1%329.9%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$19.19M USD-29.2%-8.6%—
SGHTSight Sciences, Inc.LTM Mar 2026$12.72M USD-28.5%-13.9%16.0%
CVRXCVRx, Inc.LTM Mar 2026$11.7M USD+10.5%+3.8%19.8%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$7.58M USD—+1.8%5.6%
ACBAurora Cannabis Inc.LTM Mar 2026CA$4.98M CAD+35.4%+1.4%1.6%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.25M USD-8.0%-34.3%5.4%
CGCCanopy Growth CorporationLTM Mar 2026CA$0 CAD-100.0%—0.0%
Peer median (excluding LFCR) —+10.5%-2.9%17.9%

Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
May 2021
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
Revenue100.87M111.27M103.27M128.26M128.87M
Cost of Revenue61.94M72.2M75.28M86.41M88.57M
Gross Profit38.94M39.07M27.99M41.85M40.3M
Gross Margin38.6%35.1%27.1%32.6%31.3%
Research & Development6.68M7.84M8.74M8.58M8.26M
Selling, General & Admin27.72M34.66M38.97M40.46M44.05M
Operating Expenses47.76M50.86M49.78M50.69M57.54M
Depreciation & Amortization19.87M18.06M13.18M8M8.03M
EBITDA(987K)12.84M(33.17M)35.6M(8.81M)
EBITDA Margin-1.0%11.5%-32.1%27.8%-6.8%
Operating Income(8.82M)(11.79M)(21.8M)(8.84M)(17.25M)
Operating Margin-8.7%-10.6%-21.1%-6.9%-13.4%
Interest Income48K81K68K00
Interest Expense8.93M15.55M17.65M18.09M21.84M
Other Income / Expenses(20.96M)(8.9M)(42.13M)18.36M(21.43M)
Income Before Tax(29.79M)(20.69M)(63.93M)9.51M(38.67M)
Pre-Tax Margin-29.5%-18.6%-61.9%7.4%-30.0%
Income Tax Expense(6.35M)(5.21M)308K183K43K
Net Income(32.29M)(116.72M)(99.56M)12.01M(38.72M)
Net Margin-32.0%-104.9%-96.4%9.4%-30.0%
EPS (Basic)(1.12)(3.97)(3.32)0.39(1.27)
EPS (Diluted)(1.12)(3.97)(3.32)0.33(1.27)
Weighted Avg Shares29.29M29.47M29.96M30.47M34.82M
Weighted Avg Shares (Diluted)29.29M29.47M29.96M36.66M34.82M

Lifecore Biomedical, Inc.

NASDAQ:LFCR

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.